Figure 3.

Digitized pharmacokinetic (PK) interrogation of all drugs calculated to have a peak plasma concentration (C_max)/half‐maximal effective concentration (EC₅₀) ratio above 1. The lowest reported severe acute respiratory syndrome‐coronavirus 2 EC₅₀ (dashed orange lines) and associated recalculated effective concentration 90% (EC₉₀; dashed green lines) are also highlighted. References for the utilized data are nitazoxanide 500 mg b.i.d. and 1,000 mg b.i.d., ⁹⁵ tipranavir 500 mg b.i.d. with 200 mg ritonavir, ⁹⁶ sulfadoxine 1,500 mg with 75 mg pyrimethamine, ⁸² nelfinavir 1,250 mg b.i.d., ⁹⁷ indomethacin 50 mg t.i.d., ⁹⁸ atazanavir 300 mg q.d. with 100 mg ritonavir, ⁹⁹ hydroxychloroquine 2,000 mg hydroxychloroquine sulfate/1,550 mg base administered over 3 days, ¹⁰⁰ eltrombopag 75 mg single dose, ¹⁰¹ lopinavir 400 mg with 100 mg ritonavir, ¹⁰² chloroquine 1,500 mg administered over 3 days, ¹⁰³ mefloquine 1,200 mg over 3 days, ¹⁰⁴ and anidulafungin 100 mg q.d. ¹⁰⁵ Robust PK data were unavailable for niclosamide 500 mg, ritonavir 600 mg, and merimepodib 300 mg in order to conduct this digitized interrogation of these molecules.